ArticleScientific reports2025
Investigating the effects of miR-526b and miR-655 on doxorubicin sensitivity in breast cancer.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Doxorubicin is an effective treatment for breast cancer, but drug resistance poses a significant challenge. Emerging regulators of drug resistance include microRNAs, small non-coding RNAs. Two miRNAs, miR-526b and miR-655, promote aggressive breast cancer phenotypes like cell proliferation, cancer stem cell upregulation, altered response to oxidative and metabolic stress and help tumor metastasis by activating COX-2/EP4/PI3K pathways. However, their impact on the effects of chemotherapeutic treatments remains unexplored. This study investigates the impact of overexpressing miR-526b and miR-655 on doxorubicin responses in breast cancer, focusing on pro-survival, apoptotic, and DNA-damage response pathways. We confirm the role of PI3K/Akt signalling in promoting cell survival and resistance in response to doxorubicin in vitro, though key differences exist between each cell line. High-throughput analysis of doxorubicin-exposed breast cancer cell lines, revealing novel mechanisms of miR-526b and miR-655. Overexpression of miR-526b and miR-655 may alter doxorubicin efficacy through mechanisms like DNA damage response changes, metabolic reprogramming, and immune pathway activation. Further investigation may uncover new therapeutic strategies to improve treatment efficacy and patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.